September 1, 2023 09:13 AM EDTUpdated 12:30 PM

Amgen and Horizon can close their $28B deal after resolving lawsuit by the FTC

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

Amgen has settled with the Federal Trade Commission after the US regulator in May had tried blocking the California drugmaker’s proposed nearly $28 billion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen and Horizon can close their $28B deal after resolving lawsuit by the FTC

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Am­gen and Hori­zon can close their $28B deal af­ter re­solv­ing law­suit by the FTC

Senior Reporter

Senior Editor

Sign up to read this article for free.

Amgen and Horizon can close their $28B deal after resolving lawsuit by the FTC